Roivant Sciences Ltd’s filing revealed that its 10% Owner Ramaswamy Vivek unloaded Company’s shares for reported $6.99 million on May 07 ’25. In the deal valued at $11.18 per share,625,000 shares were sold. As a result of this transaction, Ramaswamy Vivek now holds 39,174,611 shares worth roughly $424.65 million.
Then, Ramaswamy Vivek sold 273,959 shares, generating $3,142,310 in total proceeds. Upon selling the shares at $11.47, the 10% Owner now owns 39,799,611 shares.
Before that, Ramaswamy Vivek bought 625,000 shares. Roivant Sciences Ltd shares valued at $6,987,388 were divested by the 10% Owner at a price of $11.18 per share.
Wolfe Research initiated its Roivant Sciences Ltd [ROIV] rating to an Outperform in a research note published on February 15, 2024; the price target was $17. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in early January with a ‘”an Overweight”‘ rating. Deutsche Bank began covering ROIV with “Buy” recommendation on December 12, 2023. Guggenheim started covering the stock on October 17, 2023. It rated ROIV as “a Buy”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 0.46% to $10.84. Over the last five days, the stock has lost -1.36%. Roivant Sciences Ltd shares have fallen nearly -8.37% since the year began. Nevertheless, the stocks have fallen -5.74% over the past one year.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-04-30, growing by 7.63 million shares to a total of 52.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 45.1 million shares. There was a rise of 14.48%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 08, 2023 when BofA Securities began covering the stock and recommended ‘”a Neutral”‘ rating along with a $10.50 price target.
